HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.720

-0.220-2.01%

Volume:647.50K

Turnover:6.67M

Market Cap:4.36B

PE:-12.05

High:10.720

Open:10.590

Low:10.090

Close:10.940

52wk High:246.000

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.19

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.889

ROE:-36.78%

ROA:-20.32%

PB:4.25

PE(LYR):-12.05

PS:105.17

Loading ...

Overview Company News Filings

TRANSTHERA-B Unveils Key Phase II Clinical Data for Tinengotinib in Advanced Cholangiocarcinoma at 2026 ASCO

HKEX's Tech 100 Index Undergoes Semi-Annual Rebalance: Seven New Entrants Including DEEPEXI TECH

TransThera Sciences Completes HK$157 Million Share Offering

MT Newswires Live

TransThera Completes HK$156.62 Million H-Share Placement, Enlarges Share Capital by 0.94%

Bulletin Express

TRANSTHERA-B Completes Placement of 3.836 Million Shares

TransThera Sciences places 3,836,000 new H shares at HK$ 40.83 each under general mandate

TransThera Sciences Gets China Approval for Cancer Study; to Partner with Shanghai Allist Pharma on Phase 2 Trial

MT Newswires Live

TRANSTHERA-B Shares Surge Over 8% on Approval of Phase II Trial for mCRPC Treatment

TransThera Sets 18 June 2026 Virtual AGM; Shareholders to Vote on FY 2025 Results, Auditor Renewal and Supervisory Committee Cancellation

Bulletin Express

TRANSTHERA-B Calls 18 June 2026 Virtual AGM; To Address 2025 Losses, No Dividend, Auditor Re-appointment and Governance Reshuffle

Bulletin Express

TransThera Sciences announces annual shareholder meeting

TRANSTHERA-B's Core Drug, Tinengotinib, Gains NMPA Approval for Phase II Trial in Advanced Prostate Cancer

TransThera says China NMPA clears Phase II trial of tinengotinib combo in advanced prostate cancer

TRANSTHERA-B Forges Clinical and Supply Partnership with Shanghai Allist Pharmaceuticals

Transthera Sciences (Nanjing) Inc - to Conduct Phase Ii Trial of Tt-973-MS and Firmonertinib in Advanced Nsclc

THOMSON REUTERS

Transthera Sciences (Nanjing) Inc - Co and Shanghai Allist Announce Collaboration for Nsclc Clinical Trial

THOMSON REUTERS

TransThera Sciences signs pact with Allist Pharma to study TT-00973 plus firmonertinib in EGFR-mutant NSCLC

TransThera Sets 18 June 2026 Online EGM to Approve New H Share Award Scheme and Service Provider Sublimit

Bulletin Express

TransThera Sciences Launches 2026 H-Share Award Scheme, Capping New Share Issuance at 10% of Outstanding Stock

Bulletin Express

TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/02617/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.72,"timestamp":1790928489006,"preClose":10.94,"halted":0,"volume":647500,"delay":0,"changeRate":-0.020109689213893864,"floatShares":312000000,"shares":407000000,"eps":-0.8892948285333123,"marketStatus":"Market Closed","change":-0.22,"latestTime":"10-02 16:08:09","open":10.59,"high":10.72,"low":10.09,"amount":6668120,"amplitude":0.057587,"askPrice":10.8,"askSize":1500,"bidPrice":10.45,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.7869955000078475,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.94,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"volumeRatio":0.18762133812190177,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.889295,"volumeRatio":0.18762133812190177,"shares":407000000,"dividePrice":0,"high":10.72,"amplitude":0.057587,"preClose":10.94,"low":10.09,"week52Low":9.01,"pbRate":"4.25","psRate":"105.17","week52High":246,"institutionHeld":0,"latestPrice":10.72,"committee":0.142857,"eps":-0.8892948285333123,"divideRate":0,"volume":647500,"delay":0,"ttmEps":-0.7869955000078475,"open":10.59,"prevYearClose":114.9,"prevWeekClose":10.03,"prevMonthClose":10.94,"prevQuarterClose":10.94,"fiveDayClose":10.33,"twentyDayClose":10.09,"sixtyDayClose":10.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-09-30","current":-13.621425,"percent":0.790476,"low":-380.446233,"twenty":-182.105406,"median":-69.048632,"eighty":-13.947457,"high":-10.87103,"avg":-105.736079,"sd":96.27792,"marketCap":4455518845},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-11","current":-12.187879,"twenty":-194.548173,"median":-71.729981,"eighty":-33.11771,"marketCap":3824237184},{"date":"2026-09-18","current":-13.02239,"twenty":-188.179892,"median":-71.163303,"eighty":-16.078674,"marketCap":4091423888},{"date":"2026-09-25","current":-13.026466,"twenty":-182.801065,"median":-69.75013,"eighty":-14.040359,"marketCap":4084904388},{"date":"2026-09-30","current":-14.181871,"twenty":-182.105406,"median":-69.048632,"eighty":-13.947457,"marketCap":4455518845}],"updateTime":1790982102985},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1126409720","title":"TRANSTHERA-B Unveils Key Phase II Clinical Data for Tinengotinib in Advanced Cholangiocarcinoma at 2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=1126409720","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126409720?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:10","pubTimestamp":1780222228,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced the presentation of its latest research findings for its core product, tinengotinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108594441","title":"HKEX's Tech 100 Index Undergoes Semi-Annual Rebalance: Seven New Entrants Including DEEPEXI TECH","url":"https://stock-news.laohu8.com/highlight/detail?id=1108594441","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108594441?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:15","pubTimestamp":1780053358,"startTime":"0","endTime":"0","summary":"On May 29, Hong Kong Exchanges and Clearing Limited (HKEX) announced the results of the semi-annual review for the HKEX Tech 100 Index. The index will add seven technology stocks: DEEPEXI TECH...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01729","BK1610","IE00BKZH1Z71.USD","SG9999002463.SGD","BK1116","LU0210527791.USD","LU0516423091.SGD","LU0762540952.USD","02525","LU0164880469.USD","LU0918141705.HKD","LU0140636845.USD","LU0831103253.SGD","LU0821914370.USD","LU0307460666.USD","LU0072913022.USD","LU0540923850.HKD","BK1523","LU0577902611.USD","LU0898667661.SGD","IE00BZ08YS42.EUR","LU0979878070.USD","LU0577902538.SGD","LU0384037296.USD","IE00BZ08YT58.USD","BK1183","LU0488056044.USD","02617","LU0650527681.SGD","LU0117844026.USD","BK1131","LU1051768304.USD","LU1642822792.SGD","LU0067412154.USD","LU0762542818.HKD","LU1981816686.USD","IE0003851619.USD","LU0348735423.USD","HKXCY","LU0791590937.USD","LU0084288322.USD","LU0797268264.HKD","LU0348825331.USD","LU0501845795.SGD","LU0955623706.USD","LU0149721374.USD","LU0605514214.HKD","LU0762541174.USD","LU0577902371.SGD","LU1282649067.USD","LU0082770016.SGD","LU0359201885.HKD","80388","LU0348827113.USD","LU0651947912.USD","LU1048588211.SGD","IE0003795394.USD","LU0348766576.USD","LU0052750758.USD","LU2226246903.HKD","LU0516422440.USD","SGXZ90724238.SGD","LU0873338254.USD","BK1521","LU1242518931.SGD","LU1282648689.USD","IE00BZ08YR35.GBP","LU0197773673.USD","LU2039709279.SGD","LU0359201612.USD","LU0149534421.HKD","LU0516423174.USD","LU1993786604.SGD","LU0561508036.HKD","LU0588546209.SGD","LU0516422366.SGD","LU0955648018.USD","SG9999002562.SGD","LU1481107354.HKD","LU0651946864.USD","LU0594300179.USD","LU1366334651.USD","LU0572944931.SGD","LU0577902298.EUR","LU1282649810.SGD","LU0359202008.SGD","BK1589","LU0348767384.USD","LU1328277881.USD","LU1023057109.AUD","LU2257852520.SGD","02590","BK1117","LU0630378429.USD","LU1504937902.USD","LU1211504680.USD","LU0831093199.SGD","LU1734074674.USD","LU0117841782.USD","LU0320764599.SGD","BK1149","LU1105468828.SGD","LU0048580855.USD","LU1130305938.SGD","LU0327786744.USD","LU1044874839.SGD","LU0819123356.HKD","LU0516422952.EUR","LU0169518387.USD","BK1144","LU0196878994.USD","LU1813983027.USD","LU0370786039.SGD","BK1161","LU0856984785.SGD","LU0417516902.SGD","LU1282649141.HKD","LU0886674414.USD","01384","LU0274383008.USD","LU0061477393.USD","LU0577902454.USD","02643","LU1366334578.USD","SG9999001846.SGD","LU0251144936.SGD","LU1048596156.SGD","BK1506","LU0708995583.HKD","LU1655091459.SGD","SG9999006597.SGD","LU0417516738.SGD","LU1831875114.USD","LU1051769294.HKD","LU0607220059.USD","LU0197773160.USD","LU0048597586.USD","LU1044876610.USD","LU0106959298.USD","SG9999001051.SGD","SG9999001093.SGD","LU0043850808.USD","LU0165289439.USD","HSAI","LU1044875133.USD","LU0456846285.SGD","HK0000151867.HKD","LU1807302812.USD","LU2449936058.SGD","LU0648948544.HKD","LU0261947096.USD","LU1242518857.USD","LU0348816934.USD","HK0000107257.USD","BK1255","LU0211977185.USD","LU1226287529.USD","LU0791591158.USD","LU0630378692.HKD","LU0918141887.USD","LU0072462343.USD","LU0819121731.USD","IE00B3T34201.USD","LU0096374516.USD","06869","LU0594300419.USD","LU1515016050.SGD","SG9999004220.SGD","LU0164939612.USD","LU0955669360.SGD","LU0314109678.HKD","LU0620787316.HKD","LU0634319403.HKD","LU0348814723.USD","LU0082770016.USD","LU0011963245.USD","601869","LU0784639295.USD","00388"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638512654","title":"TransThera Sciences Completes HK$157 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2638512654","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638512654?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:56","pubTimestamp":1779944187,"startTime":"0","endTime":"0","summary":"TransThera Sciences   said it completed a HK$156.6 million share offering, according to a Wednesday filing with the Hong Kong bourse.The drugmaker's shares fell over 5% in late morning trade Thursday.The company sold 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product, tinengotinib.The shares represent 1.23% of the company's existing H shares and 0.94% of its enlarged share capital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182101486","title":"TransThera Completes HK$156.62 Million H-Share Placement, Enlarges Share Capital by 0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182101486","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182101486?lang=en_us&edition=fundamental","pubTime":"2026-05-27 21:02","pubTimestamp":1779886972,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera) has finalised the placement of 3.84 million new H shares at HK$40.83 each, generating gross proceeds of HK$156.62 million. Net of fees and expenses,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184062559","title":"TRANSTHERA-B Completes Placement of 3.836 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1184062559","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184062559?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:58","pubTimestamp":1779886734,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced that all conditions under the placement agreement have been fulfilled, and the placement was completed on May 27, 2026. The placing agent successfully placed a total of 3.836 million shares to no fewer than six placees at a placing price of HK$40.83 per share.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688216","title":"TransThera Sciences places 3,836,000 new H shares at HK$ 40.83 each under general mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688216","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688216?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:55","pubTimestamp":1779886533,"startTime":"0","endTime":"0","summary":"Transthera Sciences  completed a placement of 3,836,000 new H shares at HK$ 40.83 per share on May 27, 2026.Gross proceeds totaled HK$ 156.62 million; net proceeds were HK$ 152.13 million, implying a net issue price of HK$ 39.66.Net proceeds earmarked 90% for Tinengotinib new-indication development; 10% for working capital and general corporate purposes.Placed to at least six investors; none became a substantial shareholder immediately following completion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 27, 2026, and is solely responsible for the informati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL2Lt9qs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638579576","title":"TransThera Sciences Gets China Approval for Cancer Study; to Partner with Shanghai Allist Pharma on Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638579576","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638579576?lang=en_us&edition=fundamental","pubTime":"2026-05-27 13:54","pubTimestamp":1779861286,"startTime":"0","endTime":"0","summary":"TransThera Sciences   said Chinese regulators approved its phase 2 clinical trial of tinengotinib to treat prostate cancer, according to a Tuesday filing with the Hong Kong bourse.The company's shares fell over 3% in afternoon trade Wednesday.The firm will evaluate a combination of tinengotinib and novel hormone therapy in an open-label study in subjects with metastatic castration-resistant prostate cancer.In a separate announcement, the firm said it is partnering with Shanghai Allist Pharmaceuticals on another open-label phase 2 study to evaluate TT-00973-MS tablets in combination with firmonertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer.Based on the results of the study, the parties may collaborate on a phase 3 study.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133717342","title":"TRANSTHERA-B Shares Surge Over 8% on Approval of Phase II Trial for mCRPC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1133717342","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133717342?lang=en_us&edition=fundamental","pubTime":"2026-05-27 09:34","pubTimestamp":1779845680,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) opened higher by more than 8%. As of the time of writing, the stock is up 8.12% to HK$43.92, with a turnover of HK$2.1082 million. On the news front, on May 26, TRANSTHERA-B...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK4585","BK4588","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166846465","title":"TransThera Sets 18 June 2026 Virtual AGM; Shareholders to Vote on FY 2025 Results, Auditor Renewal and Supervisory Committee Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=1166846465","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166846465?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:43","pubTimestamp":1779810224,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (“TransThera-B”) has convened its 2025 annual general meeting (AGM) for 10:30 a.m. on 18 June 2026. The meeting will be held entirely online via the Vistra eVoting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126809826","title":"TRANSTHERA-B Calls 18 June 2026 Virtual AGM; To Address 2025 Losses, No Dividend, Auditor Re-appointment and Governance Reshuffle","url":"https://stock-news.laohu8.com/highlight/detail?id=1126809826","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126809826?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:06","pubTimestamp":1779808019,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (TransThera Sciences (Nanjing), Inc.) has scheduled its 2026 Annual General Meeting (AGM) for 18 June 2026 at 10:30 a.m. via the Vistra eVoting Portal. Key items on the agenda include: •...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638545673","title":"TransThera Sciences announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638545673","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638545673?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:06","pubTimestamp":1779807964,"startTime":"0","endTime":"0","summary":"Transthera Sciences  will hold its annual general meeting as a virtual meeting on June 18, 2026.Shareholders will vote on the 2025 board report, supervisory committee report, audited consolidated financial statements, annual report, profit distribution plan, and uncovered losses.Items also include reappointing Ernst & Young as 2026 auditor, setting 2026 pay plans for directors and supervisors, and appointing Feng Weibo as an independent director.Special resolutions cover mandates to issue shares, repurchase H shares, extend the issuance mandate by shares repurchased, and cancel the supervisory committee.Proposals also include changes to the business scope, amendments to the articles of association, and updates to related appendices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL3FDR9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1095","BK1161","BK1615","02617","09898"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139428390","title":"TRANSTHERA-B's Core Drug, Tinengotinib, Gains NMPA Approval for Phase II Trial in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1139428390","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139428390?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:42","pubTimestamp":1779802941,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that its core product, Tinengotinib (TT00420), in combination with novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510954","title":"TransThera says China NMPA clears Phase II trial of tinengotinib combo in advanced prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510954","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638510954?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:38","pubTimestamp":1779802730,"startTime":"0","endTime":"0","summary":"Transthera Sciences won China NMPA clearance on May 25, 2026 to start a Phase II trial of tinengotinib with novel hormone therapy in mCRPC.Study targets patients whose metastatic castration-resistant prostate cancer progressed on prior treatments; trial will assess safety, efficacy, pharmacokinetics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL48My5P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150771470","title":"TRANSTHERA-B Forges Clinical and Supply Partnership with Shanghai Allist Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=1150771470","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150771470?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:38","pubTimestamp":1779802707,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced a clinical collaboration and drug supply agreement with Shanghai Allist Pharmaceuticals Co.,Ltd. (Shanghai Allist Pharmaceuticals). The two companies will jointly...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","688578","02617","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638751032","title":"Transthera Sciences (Nanjing) Inc - to Conduct Phase Ii Trial of Tt-973-MS and Firmonertinib in Advanced Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2638751032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638751032?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230IV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638251086","title":"Transthera Sciences (Nanjing) Inc - Co and Shanghai Allist Announce Collaboration for Nsclc Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638251086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638251086?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638351080","title":"TransThera Sciences signs pact with Allist Pharma to study TT-00973 plus firmonertinib in EGFR-mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2638351080","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638351080?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802134,"startTime":"0","endTime":"0","summary":"TransThera entered a clinical trial collaboration and supply agreement with Allist to test TT-00973-MS with firmonertinib in EGFR-mutant NSCLC.Parties will run a multi-center, open-label Phase II study in locally advanced or metastatic patients to assess safety, efficacy of the combination.TransThera will sponsor the trial, covering operations and costs; Allist will supply firmonertinib mesylate tablets at no charge.Results will guide talks on a potential Phase III trial for the combination regimen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 26, 2026, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL1VvBRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161999293","title":"TransThera Sets 18 June 2026 Online EGM to Approve New H Share Award Scheme and Service Provider Sublimit","url":"https://stock-news.laohu8.com/highlight/detail?id=1161999293","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161999293?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:23","pubTimestamp":1779463424,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. will convene an extraordinary general meeting (EGM) on 18 June 2026 at 9:00 a.m. via the Vistra eVoting Portal. Shareholders will vote by poll on one special and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176623290","title":"TransThera Sciences Launches 2026 H-Share Award Scheme, Capping New Share Issuance at 10% of Outstanding Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1176623290","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176623290?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:23","pubTimestamp":1779463394,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (abbrev. “TransThera Sciences”) has received shareholder approval for a new 10-year H-Share Award Scheme aimed at enhancing staff motivation, strengthening...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145272584","title":"TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1145272584","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145272584?lang=en_us&edition=fundamental","pubTime":"2026-05-19 11:24","pubTimestamp":1779161061,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) experienced significant volatility in its share price this morning. The stock initially plunged over 9% to an intraday low of HKD 45.24 before staging a strong rebound to HKD...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02617","BK4588","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":134,"code":"91000000","status":"200"}]}}